Background The COVID-19 pandemic led to an unprecedented relaxation of restrictions on
take-home doses in opioid agonist treatment (OAT). We conducted a mixed methods …

Objective To identify, assess, and summarize the measures to assess burden of treatment in
patients with multimorbidity (BoT-MMs) and their measurement properties. Study design and …

Introduction Stigma has corrosive effects on all aspects of care and can undermine
individual and population health outcomes. Addiction-related stigma has implications for …

Background Long-acting injectable depot buprenorphine is an important new treatment
option for the management of opioid dependence, delivering therapeutic doses in weekly or …

We examine how extended-release buprenorphine depot (BUP-XR) is put to use and made
to work in implementation practices, attending to how care practices are challenged and …

Background Opioid agonist treatment (OAT) is an effective intervention for opioid
dependence. Extended-release buprenorphine injections (BUP-XR) may have additional …

Aims: This study examined the social, material and temporal effects of extended-release
buprenorphine depot treatment (BUP-XR), among a group of participants commencing BUP …

Abstract Background and Aims Long‐acting injectable buprenorphine (LAIB) is a new
treatment for opioid use disorder that is generating positive outcomes. Negative effects are …

Long-acting buprenorphine formulations have been recently marketed for the Opioid Agonist
Treatment (OAT) of opioid use disorder (OUD) associated with medical, social, and …

Background Long-acting injectable depot buprenorphine has become an important
treatment option for the management of opioid dependence. However, little is known about …